Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN1047 |
Synonyms | |
Therapy Description |
GEN1047 is a bispecific antibody that targets CD3 and VTCN1 (B7H4), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN1047 | GEN 1047|GEN-1047 | CD3 Antibody 99 | GEN1047 is a bispecific antibody that targets CD3 and VTCN1 (B7H4), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2021;9) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05180474 | Phase Ib/II | GEN1047 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | BEL | 0 |